CDT Equity Inc. (NASDAQ:CDT) Sees Large Growth in Short Interest

CDT Equity Inc. (NASDAQ:CDT) was the target of a significant increase in short interest during the month of August. As of August 31st, there was short interest totaling 42,243 shares, an increase of 324.4% from the August 15th total of 9,954 shares. Based on an average daily volume of 141,321 shares, the short-interest ratio is presently 0.3 days. Approximately 5.8% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Wall Street Zen upgraded shares of CDT Equity from a “sell” rating to a “hold” rating in a research report on Saturday, August 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of CDT Equity in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, CDT Equity currently has a consensus rating of “Sell”.

CDT Equity Stock Performance

Shares of NASDAQ:CDT traded down $0.09 on Friday, hitting $0.25. 9,753,906 shares of the company were exchanged, compared to its average volume of 2,614,759. The company’s 50 day moving average price is $2.67 and its two-hundred day moving average price is $36.07. The firm has a market capitalization of $197,500.00, a price-to-earnings ratio of -0.00 and a beta of 1.48. CDT Equity has a one year low of $0.23 and a one year high of $2,360.00.

CDT Equity (NASDAQ:CDT) last issued its earnings results on Wednesday, August 12th. The company reported ($8.71) EPS for the quarter.

About CDT Equity

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.